No matter how brilliant an academic program is, it won't become a commercial reality until a biopharma comes along, picks it up and proves it works in the clinic. Today Xconomy's Luke Timmerman tells the tale of a Seattle start-up called Blaze Bioscience, which has rounded up $725,000 in seed money to start work on new technology that promises to guide surgeons removing cancerous tissue from a patient. Story